Description | microRNAs (miRNAs) are small non-coding RNA sequences important for gene regulation. This miR-9a-5p miRNA inhibitor is designed to bind to miR-9a-5p mature miRNA, inhibiting its effect on the cell. This miRNA inhibitor can be used in experiments to investigate miRNA targets and roles in the cell. |
SKU | 10011746 |
Accession Number | MIMAT0000781 |
Description | This miRNA AAV vector is part of abm’s AAV Expression System and can be packaged into virus using an appropriate packaging mix to over-express your miRNA of interest in a wide range of host cells or animal models. |
SKU | Amr3066300 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | AAV Vector |
Reporter | GFP |
Serotype | N/A |
Vector Map | pAAV-mir-OFF-hGH-amp |
Format | Vector |
Insert | Anti-miRNA |
QC | Restriction Enzyme Digest and Sequencing |
Storage Condition | AAV Vectors are shelf stable for 1 year when stored at -20°C or below. Shipping and short term storage are acceptable at ambient temperature. Avoid repeated freeze-thaw cycles. |
Recommended Controls | pAAV-miR-Off-Blank (Cat# Am00700) |
Mammalian Selection Marker | Puromycin |
Bacterial Selection | Ampicillin |
Unit quantity | 500 ng |
Disclaimer | 1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out. |
Description | This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models. |
SKU | Amr3066301 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | AAV Virus |
Reporter | GFP |
Serotype | AAV Serotype 1 |
Vector Map | pAAV-mir-OFF-hGH-amp |
Titer | >1 x 109 GC/ml |
Format | Virus |
Insert | Anti-miRNA |
QC | qPCR Based Titer Determination and Transduction Efficiency Test |
Storage Condition | AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles. |
Recommended Controls | AAV-miR-Off-Blank Serotype 1 (Cat# Am00701) |
Mammalian Selection Marker | Puromycin |
Bacterial Selection | Ampicillin |
Unit quantity | 5 x 200 μl |
Disclaimer | 1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out. |
Description | This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models. |
SKU | Amr3066302 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | AAV Virus |
Reporter | GFP |
Serotype | AAV Serotype 2 |
Vector Map | pAAV-mir-OFF-hGH-amp |
Titer | >1 x 109 GC/ml |
Format | Virus |
Insert | Anti-miRNA |
QC | qPCR Based Titer Determination and Transduction Efficiency Test |
Storage Condition | AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles. |
Recommended Controls | AAV-miR-Off-Blank Serotype 2 (Cat# Am00702) |
Mammalian Selection Marker | Puromycin |
Bacterial Selection | Ampicillin |
Unit quantity | 5 x 200 μl |
Disclaimer | 1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out. |
Description | This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models. |
SKU | Amr3066303 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | AAV Virus |
Reporter | GFP |
Serotype | AAV Serotype 3 |
Vector Map | pAAV-mir-OFF-hGH-amp |
Titer | >1 x 109 GC/ml |
Format | Virus |
Insert | Anti-miRNA |
QC | qPCR Based Titer Determination and Transduction Efficiency Test |
Storage Condition | AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles. |
Recommended Controls | AAV-miR-Off-Blank Serotype 3 (Cat# Am00703) |
Mammalian Selection Marker | Puromycin |
Bacterial Selection | Ampicillin |
Unit quantity | 5 x 200 μl |
Disclaimer | 1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out. |
Description | This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models. |
SKU | Amr3066304 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | AAV Virus |
Reporter | GFP |
Serotype | AAV Serotype 4 |
Vector Map | pAAV-mir-OFF-hGH-amp |
Titer | >1 x 109 GC/ml |
Format | Virus |
Insert | Anti-miRNA |
QC | qPCR Based Titer Determination and Transduction Efficiency Test |
Storage Condition | AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles. |
Recommended Controls | AAV-miR-Off-Blank Serotype 4 (Cat# Am00704) |
Mammalian Selection Marker | Puromycin |
Bacterial Selection | Ampicillin |
Unit quantity | 5 x 200 μl |
Disclaimer | 1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out. |
Description | This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models. |
SKU | Amr3066305 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | AAV Virus |
Reporter | GFP |
Serotype | AAV Serotype 5 |
Vector Map | pAAV-mir-OFF-hGH-amp |
Titer | >1 x 109 GC/ml |
Format | Virus |
Insert | Anti-miRNA |
QC | qPCR Based Titer Determination and Transduction Efficiency Test |
Storage Condition | AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles. |
Recommended Controls | AAV-miR-Off-Blank Serotype 5 (Cat# Am00705) |
Mammalian Selection Marker | Puromycin |
Bacterial Selection | Ampicillin |
Unit quantity | 5 x 200 μl |
Disclaimer | 1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out. |
Description | This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models. |
SKU | Amr3066306 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | AAV Virus |
Reporter | GFP |
Serotype | AAV Serotype 6 |
Vector Map | pAAV-mir-OFF-hGH-amp |
Titer | >1 x 109 GC/ml |
Format | Virus |
Insert | Anti-miRNA |
QC | qPCR Based Titer Determination and Transduction Efficiency Test |
Storage Condition | AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles. |
Recommended Controls | AAV-miR-Off-Blank Serotype 6 (Cat# Am00706) |
Mammalian Selection Marker | Puromycin |
Bacterial Selection | Ampicillin |
Unit quantity | 5 x 200 μl |
Disclaimer | 1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out. |
Description | This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models. |
SKU | Amr3066307 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | AAV Virus |
Reporter | GFP |
Serotype | AAV Serotype 7 |
Vector Map | pAAV-mir-OFF-hGH-amp |
Titer | >1 x 109 GC/ml |
Format | Virus |
Insert | Anti-miRNA |
QC | qPCR Based Titer Determination and Transduction Efficiency Test |
Storage Condition | AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles. |
Recommended Controls | AAV-miR-Off-Blank Serotype 7 (Cat# Am00707) |
Mammalian Selection Marker | Puromycin |
Bacterial Selection | Ampicillin |
Unit quantity | 5 x 200 μl |
Disclaimer | 1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out. |
Description | This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models. |
SKU | Amr3066308 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | AAV Virus |
Reporter | GFP |
Serotype | AAV Serotype 8 |
Vector Map | pAAV-mir-OFF-hGH-amp |
Titer | >1 x 109 GC/ml |
Format | Virus |
Insert | Anti-miRNA |
QC | qPCR Based Titer Determination and Transduction Efficiency Test |
Storage Condition | AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles. |
Recommended Controls | AAV-miR-Off-Blank Serotype 8 (Cat# Am00708) |
Mammalian Selection Marker | Puromycin |
Bacterial Selection | Ampicillin |
Unit quantity | 5 x 200 μl |
Disclaimer | 1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out. |
Description | This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models. |
SKU | Amr3066309 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | AAV Virus |
Reporter | GFP |
Serotype | AAV Serotype 9 |
Vector Map | pAAV-mir-OFF-hGH-amp |
Titer | >1 x 109 GC/ml |
Format | Virus |
Insert | Anti-miRNA |
QC | qPCR Based Titer Determination and Transduction Efficiency Test |
Storage Condition | AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles. |
Recommended Controls | AAV-miR-Off-Blank Serotype 9 (Cat# Am00709) |
Mammalian Selection Marker | Puromycin |
Bacterial Selection | Ampicillin |
Unit quantity | 5 x 200 μl |
Disclaimer | 1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out. |
Description | This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models. |
SKU | Amr3066310 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | AAV Virus |
Reporter | GFP |
Serotype | AAV Serotype 10 |
Vector Map | pAAV-mir-OFF-hGH-amp |
Titer | >1 x 109 GC/ml |
Format | Virus |
Insert | Anti-miRNA |
QC | qPCR Based Titer Determination and Transduction Efficiency Test |
Storage Condition | AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles. |
Recommended Controls | AAV-miR-Off-Blank Serotype 10 (Cat# Am00710) |
Mammalian Selection Marker | Puromycin |
Bacterial Selection | Ampicillin |
Unit quantity | 5 x 200 μl |
Disclaimer | 1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out. |
Description | This miRNA inhibitor adenovirus is part of abm’s Adenoviral Expression System and can be used directly to transiently inhibit your miRNA of interest in a wide range of host cells. This adenovirus can be used to amplify more adenovirus by transducing HEK293 cells. For enhanced transduction efficiency, the use of ViralPlus (G698) at 1:100 is recommended at the time of transduction. |
SKU | mr5663 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | Adenovirus |
Serotype | N/A |
Vector Map | pAdeno-miR-Off |
Titer | >106pfu/ml |
Format | Virus |
Insert | Anti-miRNA |
Storage Condition | High titer adenoviruses are shipped with dry ice and low titer adenoviruses are shipped with ice packs. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles. |
Unit quantity | 1.0 ml |
Disclaimer |
abm guarantees that the correct construct is provided and GFP expression is displayed upon successful transduction. If this is not the case, we will provide a one-time replacement. Customers must provide adequate data to show >80% transfection efficiency with a positive control. The replacement will not be covered by the same guarantee.
Please note that due to the large number of variables applicable, any further expression analysis is not covered by the guarantee, as such analysis is dependent on the end user's experimental conditions.
|
Description | This ready-to-use miRNA inhibitor lentivirus is part of abm’s Lentivirus Expression System and can be used directly to inhibit your miRNA of interest in a wide range of host cells or animal models. This virus contains a GFP reporter for monitoring transduction efficiency. |
SKU | mr35663 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | Lentivirus |
Serotype | N/A |
Vector Map | pLenti-III-miR-Off |
Titer | >107 IU/ml |
Format | Virus |
Insert | Anti-miRNA |
Storage Condition | Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles. |
Unit quantity | 2 x 50 μl |
Disclaimer |
abm guarantees that the correct construct is provided and GFP expression is displayed upon successful transduction. If this is not the case, we will provide a one-time replacement. Customers must provide adequate data to show >80% transfection efficiency with a positive control. The replacement will not be covered by the same guarantee.
Please note that due to the large number of variables applicable, any further expression analysis is not covered by the guarantee, as such analysis is dependent on the end user's experimental conditions.
|
Description | This miRNA inhibitor lentiviral vector is part of abm’s Lentivirus Expression System and can be packaged into virus using an appropriate packaging mix to inhibit your miRNA of interest in a wide range of host cells or animal models. This construct contains a GFP reporter for monitoring transfection efficiency. |
SKU | mr30663 |
Features | GFP Reporter |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | Lentiviral Vector |
Serotype | N/A |
Vector Map | pLenti-III-miR-Off |
Titer | N/A |
Format | Vector |
Insert | Anti-miRNA |
Storage Condition | Store at -20°C or below upon receipt |
Unit quantity | 500 ng |
Disclaimer |
abm guarantees that the correct construct is provided and GFP expression is displayed upon successful transduction. If this is not the case, we will provide a one-time replacement. Customers must provide adequate data to show >80% transfection efficiency with a positive control. The replacement will not be covered by the same guarantee.
Please note that due to the large number of variables applicable, any further expression analysis is not covered by the guarantee, as such analysis is dependent on the end user's experimental conditions.
|
Description | microRNA Inhibitors are chemically synthesized, complementary, antisense single-stranded oligonucleotides to their target, endogenous mature miRNA. It effectively prevents the target miRNA to bind to normal cellular binding sites. Transfection of inhibitors followed by downstream gene expression analysis or phenotypic analysis, is performed to elucidate the targets and roles of particular miRNAs. miRNA Inhibitor Negative Control can be purchased separately (Cat. No. MIH000000).
Note: This synthetic miRNA is based on the mature miRNA sequence. It does not contain the full precursor miRNA stem-loop. |
SKU | MIR01868 |
Features | Inhibitor |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | Synthetic miRNA |
Serotype | N/A |
Format | Virus |
Storage Condition | -20°C |
Unit quantity | 2 x 5.0 nmol |
Description | Antagomirs are modified microRNA Inhibitors that contain several modifications on the strands that make them more resistant to degradation than normal inhibitors. The chemical modifications also make the Antagomirs to exhibit higher cell membrane binding affinity, thus resulting in higher transfection efficiency.
Note: This synthetic miRNA is based on the mature miRNA sequence. It does not contain the full precursor miRNA stem-loop. |
SKU | MNR01868 |
Features | Antagomir |
Accession Number | MIMAT0000781 |
miRNA ID | MIMAT0000781 |
miRNA Name | rno-miR-9a-5p |
Gene Name | rno-miR-9a-5p |
Species | Rat (R. norvegicus) |
System | Synthetic miRNA |
Serotype | N/A |
Format | Virus |
Storage Condition | -20°C |
Unit quantity | 2 x 5.0 nmol |